Table 20Studies reporting mean or median change from baseline

Study
Population (N)
Quality
Age (Variability)TimingResultIndex TestNResultsVariabilityClinical Scenario
Badesch, 2012171

Adults with PAH (N=224)

Good
Mean 55 (SD 16)BaselineMeanNatriuretic peptides/BNP224335SD 413Response to ambrisentan
6 moMean changeNatriuretic peptides/BNP224−2695% CI
−34 to −16
Response to ambrisentan
Barst, 199685

Adults with PPH (N=81)

Good
NR for cohort3 moMean changemPAP41−4.8SE 1.3Response to epoprostenol
Channick, 200194

Adults with PPH or PAH associated with scleroderma (N=32)

Good
NR for cohort3 moMean changemPAP20−1.6SE 1.2Response to bosentan
Hinderliter, 1997116

Adults with PPH (N=81)

Fair
NR for cohortBaselineMeanRV size3821.2SE 0.7Response to epoprostenol
BaselineMeanFractional area change3819.2SE 1.2Response to epoprostenol
BaselineMeanTR jet velocity364.3SE 0.1Response to epoprostenol
3 moMedian changeRV size330.4Response to epoprostenol
3 moMedian changeFractional area change33−2.2Response to epoprostenol
3 moMedian changeTR jet velocity32−0.04Response to epoprostenol
McLaughlin, 2010131

Adults with PAH (N=235)

Good
Mean 54 (Range 18 to 75)6 wkMedian changeNatriuretic peptides/BNP86−71p<0.0003Response to treprostinil
3moMedian changeNatriuretic peptides/BNP73−57IQR
−396.0 to 34.0
Response to treprostinil
Wilkins, 2005156

Adults with IPAH or PAH associated with CTD (N=26)

Good
NR for cohort4 moMean changeRV size12−395% CI
−7.5 to 1.5
Response to bosentan
4 moMean changeCardiac Index120.395% CI
0.1 to 0.4
p=0.01
Response to bosentan
4 moMean changeRIMP/MPI/Tei Index12−0.0295% CI
−0.1 to 0.11
Response to bosentan
4 moMean changeRA size12495% CI
−16 to 23
Response to bosentan
4 moMean changeNatriuretic peptides/BNP12−5.995% CI
−35 to 24
Response to bosentan
4 moMean changeRV size13−8.895% CI
−16 to −2
p=0.05
Response to sildenafil
4 moMean changeCardiac Index130.395% CI
0.1 to 0.4
p=0.01
Response to sildenafil
4 moMean changeRIMP/MPI/Tei Index13−0.1195% CI
−0.23 to 0.01
Response to sildenafil
4 moMean changeRA size13−495% CI
−19 to 12
Response to sildenafil
4 moMean changeNatriuretic peptides/BNP13−19.495% CI
−34 to −5
Response to sildenafil
Yoshida, 2012174

Adults with PAH (N=21)

Fair
Mean 45.6 (SD 12.6)BaselineMeanNatriuretic peptides/21191.1SD 241.4Response to ambrisentan
BaselineMeanmPAP2048.1SD 17Response to ambrisentan
6 moMean changeNatriuretic peptides/20−109.5SD 170.5Response to ambrisentan
6 moMean changemPAP21−10SD 7.4
95% CI
−13.5 to −6.4
Response to ambrisentan
1 yrMean changeNatriuretic peptides/21−70.4SD 211.5Response to ambrisentan
1 yrMean changemPAP19−7.1SD 10.1
95% CI
−11.9 to −2.2
Response to ambrisentan
2 yrMean changeNatriuretic peptides/19−117.1SD 183.8Response to ambrisentan
2 yrMean changemPAP16−10.9SD 10.8
95% CI
−16.6 to −5.1
Response to ambrisentan
3 yrMean changeNatriuretic peptides/6−146.5SD 218.6Response to ambrisentan
3 yrMean changemPAP6−13.9SD 8.9
95% CI
−23.2 to −4.5
Response to ambrisentan

BNP = B-type natriuretic peptide; CI = confidence interval; IQR = interquartile range; mPAP = mean pulmonary artery pressure; mo = month/months; MPI = myocardial performance index; NR = not reported; PVR = pulmonary vascular resistance; RA = right atrium; RIMP = right index of myocardial performance; RV = right ventricle; RVEF = right ventricle ejection fraction; SD = standard deviation; SEM = standard error of the mean; sPAP = systolic pulmonary artery pressure; TAPSE = tricuspid annular plane systolic excursion; TRV = tricuspid regurgitant jet velocity; wk = week/weeks; yr = year/years

From: Results

Cover of Pulmonary Arterial Hypertension: Screening, Management, and Treatment
Pulmonary Arterial Hypertension: Screening, Management, and Treatment [Internet].
Comparative Effectiveness Reviews, No. 117.
McCrory DC, Coeytaux RR, Schmit KM, et al.

PubMed Health. A service of the National Library of Medicine, National Institutes of Health.